---
title: "Pharmacokinetics/Pharmacodynamics (PK/PD) of Antimicrobials and Novel Agents"
subtitle: "A workshop for graduate students, pharmacy students, and postdocs"
format: 
  clean-revealjs:
    output-file: index.html
    self-contained: false
html-math-method:
  method: mathjax
  url: "https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"
author:
  - name: Jacob K. McPherson
    orcid: 0000-0001-5486-4945
    email: jacobmcpherson@utexas.edu, jkmcpherson@uh.edu, jacob@jacobkmcpherson.com
    affiliations: University of Houston College of Pharmacy
date: last-modified
---

# Welcome to the Workshop!

## This workshop was inspired by a conversation
### Between Dr. Cesar Arias, MD, PhD, and Dr. Brad spellberg, MD
<!-- this is a comment in the Quarto document, hidden from render -->

::: {style="text-align: center;"}
<iframe 
    src="https://www.youtube.com/embed/3z4BItBrzbk?si=WMiGwvZnvsreN57v"
    width="800" 
    height="450" 
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    allowfullscreen> </iframe>
:::

## Learning Objectives

-   Describe the fundamental concepts of pharmacokinetics and pharmacodynamics (PK/PD).\
-   Discuss the design and utility of PK/PD studies, including hands-on applications using R programming.
-   translate clinical PK/PD to dose optimization using R programming.
-   Identify PK/PD considerations for new drug development.

## Similar Workshops

<!-- [Workshop agenda (README.md)](https://github.com/JacobKMcPherson/workshop_pkpd_antimicrobials/blob/main/README.md#agenda-overview)\--> 
<!-- [Scholars program](https://www.gulfcoastconsortia.org/home/research/antimicrobial-resistance/amr-scholars-program/)\ -->
-   [NIAID 2017 Workshop](https://amr.solutions/wp-content/uploads/99/niaid_june2017_pkpdworkshopsummary.pdf)
-   [SIDP 2025 Workshop](https://sidp.org/PKPD)
-   [ESCMID 2026 Workshop](https://www.escmid.org/event-detail/optimised-dosing-of-antibiotics-understanding-pkpd-clinical-breakpoints-and-therapeutic-drug-monitoring-2026/)

## If this workshop is insufficient, 
### I hope these resources from the NIH Clinical Center help!

-   [NIH Clinical Center YouTube](https://www.youtube.com/NIHClinicalCenter)

## Animal Scale Up and First-in-Human Studies
### by Dr. Jerry Collins, PhD

<!-- this is a comment in the Quarto document, hidden from render -->

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/IFGcMrOHlVk?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::

## Dose Selection and Optimization
### by Dr. Yaning Wang, PhD

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/zqLkBeGp8g8?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::

## Drub Absorption and Bioavailability
### by Dr. Jan H. Beumer, PharmD, PhD

<!-- this is a comment in the Quarto document, hidden from render -->

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/bqKHy2xeIkw?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::

## Multicompartment Pharmacokinetic Modeling
### by Dr. Scott r. Penzak, PharmD, FCP

<!-- this is a comment in the Quarto document, hidden from render -->

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/H8d7MoNM6t0?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::


## Population Pharmacokinetics
### by Dr. Robert R. Bies, PharmD, PhD

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/TozOUOj2YvI?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::

## Pharmacodynamics in Drug Development
### by Dr. James Doroshow, MD

::: {style="text-align: center;"}
<iframe
    width="800"
    height="450"
    style="max-width: 80vw; aspect-ratio: 16/9; border: none;"
    src="https://www.youtube.com/embed/1qvfSMJJpQU?list=PLokeFpXsus96lkVjFsQEMtT5a-yIJKDJt"
    allowfullscreen>
</iframe>
:::

# Background Clinical Microbiology     
## You already know:
### Minimum Inhibitory Concentrations (MIC)<sup><a href="https://doi.org/10.1016/j.xpro.2023.102512">1</a></sup>

![](content/images/Barnes2023StarProtocols_mic.jpg){fig-align="center" width="60%"}

## You already know:
### Minimum Bactericidal Concentrations (MBC)<sup><a href="https://doi.org/10.1016/B978-0-12-801238-3.00244-0">2</a></sup>
![](content/images/Bury-Mone2014_mbc_mic_ratio_1.svg){fig-align="center" height="70vh" width="auto"}


## But do you know how to determine PK/PD?
### Cmax/MIC, AUC/MIC, %freeT>MIC
![](content/images/Bury-Mone2014_mbc_mic_ratio_2.svg){fig-align="center" height="70vh" width="auto"}


# Pharmacokinetics (PK) 101
## Pharmacokinetics (PK) 101
### subtitle
content

## ADME
### Absorption, Distribution, Metabolism, Excretion
content

## ADME
### Absorption
content

## ADME
### Distribution
content

## ADME
### Metabolism
content

## ADME
### Excretion
content

## Non-Compartmental (NCA) vs. Compartmental Analysis (CA)
### subtitle
content

## One- vs. Multi-Compartment Models
### subtitle
content


# PK/PD of Antimicrobials

## PK/PD of Antimicrobials
### Commonly used parameters




## The *in vitro* Hollow-Fiber Infection Model (HFIM)
### subtitle




## The *in vivo* Animal Models of Infection 
### subtitle




# Six Clinical Cases

## Six Clinical Cases
### subtitle


## Analysis of *in vitro* HFIM data
### subtitle


# Six Clinical Cases

## Six Clinical Cases
### subtitle

## Analysis via PopPK
### subtitle
